78
Participants
Start Date
September 4, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
September 30, 2027
AXT-1003
AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Hunan Cancer Hosptial, Changsha
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Sun Yat-Sen University Cancer Center, Guangzhou
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
Axter Therapeutics (Beijing) Co., Ltd
INDUSTRY